Sitagliptin therapy to improve outcomes after islet autotransplantation.

描述（由申请人提供）：Melena贝林，医学博士，是明尼苏达大学（UM）儿科内分泌学系的助理教授。在这个职位上，她将75%的时间用于胰岛移植领域以患者为导向的研究。在此职业发展奖期间的具体目标将包括：1）提高临床试验管理，免疫学和胰岛移植方面的知识; 2）每年出版2篇同行评审的手稿; 3）完成下述临床试验; 4）在此奖项的最后2年提交R系列研究资助。 博士贝林在麻省理工学院读书时接受过以病人为导向的研究方面的正式培训。临床研究在UM。她一直是胰岛移植队列研究和小型非随机临床试验的共同研究者。她将在职业发展奖期间通过与她的研究相关的更具体领域的正式培训，参加她所在领域的国家和国际会议以及进行大型随机临床试验来建立这个基础。在项目导师Antoinette Moran博士的指导下，贝林博士将进行一项随机双盲对照试验，评价全胰腺切除术和胰岛自体移植术后西格列汀治疗对胰岛素依赖性和胰岛功能的影响。该项目有两个目的：1）确定全胰腺切除术和胰岛自体移植后使用DPP-4抑制剂治疗是否增加了实现胰岛素非依赖性的受者比例，2）评估胰岛功能的术前测试是否与胰岛产量相关。虽然基于肠促胰岛素的疗法已经用于胰岛同种异体移植的非常小的非随机试验，但这将是第一个研究胰岛自体移植中这种疗法的大型随机研究。 研究项目将在糖尿病和胰岛移植研究领域经验丰富的导师和共同导师的指导下进行-Antoinette Moran博士，Bernhard Hering博士和大卫萨瑟兰博士。UM在胰岛移植方面的丰富经验使其成为这项研究的理想环境。总体学术进展将通过与咨询委员会的定期会议进行监测。 公共卫生相关性：胰岛移植是慢性胰腺炎和1型糖尿病的一种新兴治疗方法。该项目将探讨患者的特征和可能提高胰岛移植成功率的干预措施。

DESCRIPTION (provided by applicant): Melena Bellin, MD is an Assistant Professor in the Department of Pediatrics, Division of Pediatric Endocrinology, at the University of Minnesota (UM). In this position, she devotes 75% of her time to patient-oriented research in the field of islet transplantation. Specific goals during this career development award period will include: 1) improved knowledge in clinical trials management, immunology, and islet transplantation; 2) publication of 2 peer-reviewed manuscripts per year; 3) completion of a clinical trial as described below; and 4) submission of a R-series research grant in the last 2 years of this award. Dr. Bellin has had formal training in patient-oriented research as a student in the M.S. program in Clinical Research at UM. She has been a co-investigator in cohort studies and small non-randomized clinical trials in islet transplant. She will build upon this foundation during the career development award period through formal training in more specific areas related to her research, attendance at national and international conferences in her field, and by conducting a large randomized clinical trial. Under the guidance of Dr. Antoinette Moran, the project mentor, Dr. Bellin will conduct a randomized double-blinded controlled trial evaluating the effect of sitagliptin treatment following total pancreatectomy and islet autotransplant on insulin independence and islet function. This project will have two aims: 1) to determine if treatment with a DPP-4 inhibitor after total pancreatectomy and islet autotransplant increases the proportion of recipients achieving insulin independence, and 2) to evaluate whether preoperative tests of islet function correlate with islet yield. Although incretin-based therapies have been used in very small, non-randomized trials of islet allotransplantation, this will be the first large randomized study to investigate such a therapy in islet autotransplant. Research projects will be conducted under the guidance of a mentor and co-mentors experienced in the fields of diabetes and islet transplant research-- Dr. Antoinette Moran, Dr. Bernhard Hering, and Dr. David Sutherland. The extensive experience with islet transplants at UM makes this an ideal environment for this research focus. Overall scholarly progress will be monitored by regular meetings with an advisory committee. PUBLIC HEALTH RELEVANCE: Islet transplant is an emerging new treatment for chronic pancreatitis and type 1 diabetes mellitus. This project will explore patient characteristics and an intervention which may improve the success of islet transplant.